A real-world evidence study in Nature Communications compared the safety of second-line antihyperglycemic agents in older adults with type 2 diabetes mellitus. Kim, Bu, Blacketer, and colleagues analyzed real-world comparative outcomes focused on an elderly population where comorbidities and polypharmacy can complicate risk-benefit decisions. The update contributes to evidence generation beyond trial populations, supporting clinicians and health systems that increasingly rely on observational safety signals to refine prescribing. For geriatric diabetes care, the report reinforces the push for comparative effectiveness and safety characterizations that reflect how therapies perform in routine practice.